A single-arm, exploratory study of disitamab vedotin (DV) combined with camrelizumab and platinum-based chemotherapy as first-line treatment in patients with HER2 expressing locally advanced or metastatic esophageal squamous cell carcinoma (ESCC).
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Meihong Wu, Yingyi Zhang, Dan Feng, Bin Wang, Wei Wang, Tianran Chen, Anjing Zhao, Meng Xu, Linli Zhang, Xianbao Zhan
Institution: Second Military Medical University
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4401513668